Comprehensive Stock Comparison
Compare Ainos, Inc. (AIMD) vs Nautilus Biotechnology, Inc. (NAUT) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Stability / Safety |  AIMD | Beta 1.19 vs NAUT's 1.71 |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) |  NAUT | +94.6% vs AIMD's -37.3% |
| Efficiency (ROA) | NAUT | -31.3% ROA vs AIMD's -65.9% |
Who Each Stock Is For
Income & stability
AIMDDividend streak 0 yrs, beta 1.19
Growth exposure
AIMDRev growth -83.0%, EPS growth 53.6%, 3Y rev CAGR -67.3%
Long-term compounding (10Y)
NAUT-76.9% 10Y total return vs AIMD's -97.3%
Sleep-well-at-night portfolio
AIMDLower volatility, beta 1.19, Low D/E 77.3%, current ratio 1.10x
Defensive / Recession hedge
AIMDBeta 1.19, current ratio 1.10x
Business Model
What each company does and how it makes money
Ainos is a healthcare technology company developing point-of-care diagnostic tests and novel medical treatments. It generates revenue primarily from COVID-19 testing kits and related cloud-based management software — with additional income from its low-dose oral interferon alpha formulation and synthetic RNA platform. The company's competitive advantage lies in its integrated approach combining physical test kits with digital cloud-based management systems for healthcare providers.
Nautilus Biotechnology is a life sciences company developing a proteomics platform to analyze proteins at unprecedented scale and depth. It aims to generate revenue through sales of its integrated platform — including instruments, consumables, and software — though it remains pre-revenue as it develops its technology. The company's potential moat lies in its proprietary single-molecule protein analysis technology, which could enable comprehensive proteome mapping that existing methods cannot achieve.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
NAUT 2AIMD 0NAUT1/1 metricsNAUT6/6 metricsNAUT leads in 2 of 6 categories — strongest in Financial Metrics and Total Returns. 3 categories are tied.
Financial Metrics (TTM)
AIMD and NAUT operate at a comparable scale, with $113,037 and $0 in trailing revenue.
| Metric | AIMDAinos, Inc. | NAUTNautilus Biotechn… |
|---|---|---|
| RevenueTrailing 12 months | $113,037 | $0 |
| EBITDAEarnings before interest/tax | -$10M | -$60M |
| Net IncomeAfter-tax profit | -$15M | -$63M |
| Free Cash FlowCash after capex | -$5M | -$54M |
| Gross MarginGross profit ÷ Revenue | +82.7% | — |
| Operating MarginEBIT ÷ Revenue | -126.7% | — |
| Net MarginNet income ÷ Revenue | -132.3% | — |
| FCF MarginFCF ÷ Revenue | -41.2% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | -93.9% | +15.4% |
Valuation Metrics
| Metric | AIMDAinos, Inc. | NAUTNautilus Biotechn… |
|---|---|---|
| Market CapShares × price | $7M | $305M |
| Enterprise ValueMkt cap + debt − cash | $15M | $322M |
| Trailing P/EPrice ÷ TTM EPS | -0.98x | -5.13x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 353.83x | — |
| Price / BookPrice ÷ Book value/share | 0.94x | 1.94x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
NAUT delivers a -37.1% return on equity — every $100 of shareholder capital generates $-37 in annual profit, vs $-149 for AIMD. NAUT carries lower financial leverage with a 0.19x debt-to-equity ratio, signaling a more conservative balance sheet compared to AIMD's 0.77x. On the Piotroski fundamental quality scale (0–9), AIMD scores 2/9 vs NAUT's 1/9, reflecting mixed financial health.
| Metric | AIMDAinos, Inc. | NAUTNautilus Biotechn… |
|---|---|---|
| ROE (TTM)Return on equity | -148.9% | -37.1% |
| ROA (TTM)Return on assets | -65.9% | -31.3% |
| ROICReturn on invested capital | -39.8% | — |
| ROCEReturn on capital employed | -50.0% | — |
| Piotroski ScoreFundamental quality 0–9 | 2 | 1 |
| Debt / EquityFinancial leverage | 0.77x | 0.19x |
| Net DebtTotal debt minus cash | $8M | $18M |
| Cash & Equiv.Liquid assets | $4M | $12M |
| Total DebtShort + long-term debt | $12M | $30M |
| Interest CoverageEBIT ÷ Interest expense | -19.79x | — |
Total Returns (with DRIP)
A $10,000 investment in NAUT five years ago would be worth $1,646 today (with dividends reinvested), compared to $91 for AIMD. Over the past 12 months, NAUT leads with a +94.6% total return vs AIMD's -37.3%. The 3-year compound annual growth rate (CAGR) favors NAUT at 3.3% vs AIMD's -56.6% — a key indicator of consistent wealth creation.
| Metric | AIMDAinos, Inc. | NAUTNautilus Biotechn… |
|---|---|---|
| YTD ReturnYear-to-date | -12.6% | +26.3% |
| 1-Year ReturnPast 12 months | -37.3% | +94.6% |
| 3-Year ReturnCumulative with dividends | -91.8% | +10.2% |
| 5-Year ReturnCumulative with dividends | -99.1% | -83.5% |
| 10-Year ReturnCumulative with dividends | -97.3% | -76.9% |
| CAGR (3Y)Annualised 3-year return | -56.6% | +3.3% |
Risk & Volatility
AIMD is the less volatile stock with a 1.19 beta — it tends to amplify market swings less than NAUT's 1.71 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NAUT currently trades 78.3% from its 52-week high vs AIMD's 34.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | AIMDAinos, Inc. | NAUTNautilus Biotechn… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.19x | 1.71x |
| 52-Week HighHighest price in past year | $4.50 | $3.08 |
| 52-Week LowLowest price in past year | $1.26 | $0.62 |
| % of 52W HighCurrent price vs 52-week peak | +34.0% | +78.3% |
| RSI (14)Momentum oscillator 0–100 | 46.5 | 52.1 |
| Avg Volume (50D)Average daily shares traded | 821K | 160K |
Analyst Outlook
| Metric | AIMDAinos, Inc. | NAUTNautilus Biotechn… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $2.50 |
| # AnalystsCovering analysts | — | 5 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 0 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.1% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Jan 21 | Mar 26 | Change |
|---|---|---|---|
| Ainos, Inc. (AIMD) | 100 | 2.67 | -97.3% |
| Nautilus Biotechnol… (NAUT) | 100 | 21.62 | -78.4% |
Nautilus Biotechnol… (NAUT) returned -84% over 5 years vs Ainos, Inc. (AIMD)'s -99%.
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Ainos, Inc. (AIMD) | $0.00 | $20729.00 | — |
| Nautilus Biotechnol… (NAUT) | $0.00 | $0.00 | — |
Chart 3EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Ainos, Inc. (AIMD) | -0.5 | -1.56 | -212.0% |
| Nautilus Biotechnol… (NAUT) | 87.18 | -0.47 | -100.5% |
Chart 4Free Cash Flow — 5 Years
Ainos, Inc. generated $-6M FCF in 2024 (-318% vs 2021). Nautilus Biotechnology, Inc. generated $-52M FCF in 2025 (-25% vs 2021).
AIMD vs NAUT: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is AIMD or NAUT a better buy right now?
Analysts rate Nautilus Biotechnology, Inc. (NAUT) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — AIMD or NAUT?
Over the past 5 years, Nautilus Biotechnology, Inc. (NAUT) delivered a total return of -83.5%, compared to -99.1% for Ainos, Inc. (AIMD). A $10,000 investment in NAUT five years ago would be worth approximately $2K today (assuming dividends reinvested). Over 10 years, the gap is even starker: NAUT returned -76.9% versus AIMD's -97.3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — AIMD or NAUT?
By beta (market sensitivity over 5 years), Ainos, Inc. (AIMD) is the lower-risk stock at 1.19β versus Nautilus Biotechnology, Inc.'s 1.71β — meaning NAUT is approximately 44% more volatile than AIMD relative to the S&P 500. On balance sheet safety, Nautilus Biotechnology, Inc. (NAUT) carries a lower debt/equity ratio of 19% versus 77% for Ainos, Inc. — giving it more financial flexibility in a downturn.
04Which has better profit margins — AIMD or NAUT?
Nautilus Biotechnology, Inc. (NAUT) is the more profitable company, earning 0.0% net margin versus -717.0% for Ainos, Inc. — meaning it keeps 0.0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NAUT leads at 0.0% versus -667.7% for AIMD. At the gross margin level — before operating expenses — NAUT leads at 0.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — AIMD or NAUT?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is AIMD or NAUT better for a retirement portfolio?
For long-horizon retirement investors, Ainos, Inc. (AIMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.19)). Nautilus Biotechnology, Inc. (NAUT) carries a higher beta of 1.71 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AIMD: -97.3%, NAUT: -76.9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between AIMD and NAUT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.